Maz Ganat, MD
Surgical Oncology · Englewood, NJNPI 1356636500
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,395 of the $1,679 with a category attached, or 83.1%. AstraZeneca accounts for 83.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $1,395 and has fallen 94.1% since, to $82 in 2025.
Across 11 payments — averaging $152.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boston Scientific$125
- Angiodynamics, Inc.$41
- Merck$41
- Johnson & Johnson$41
- Urogen Pharma, Inc.$19
- plus $17 from 1 others
Across 2 payments — averaging $7096.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$14K
What the payments were for
- Consulting fees$1,39583%
- Food & beverage$28417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $1,395 |
| Boston Scientific | 1 | $125 |
| Angiodynamics, Inc. | 2 | $41 |
| Merck | 3 | $41 |
| Johnson & Johnson | 2 | $41 |
| Urogen Pharma, Inc. | 1 | $19 |
| Teleflex LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$1,395
- GENERAL ERECTILE DYSFUNCTION$125
How this compares
$1,679 in reported general payments places this provider in the 65th percentile of 59 surgical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 32 | $21,121 |
| Finasteride | 196 | $2,374 |
| Tamsulosin Hcl | 152 | $1,965 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 66 | $1,793 |
| Ciprofloxacin Hcl | 16 | $54 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $51 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Englewood
- Joseph KimEnglewood$6K
- Cherif BoutrosEnglewood$1K
- Violet McIntoshEnglewood$839
- Thangamani SeenivasanSomerville$22K
- John CunninghamBerkeley Heights$20K
- Manpreet KohliLong Branch$20K
- Haejin InNew Brunswick$12K
- Anjeanette BrownCape May Court House$11K
- Marc FromerBrick$9K
- Russell LanganLivingston$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.